Related references
Note: Only part of the references are listed.Cisplatin in Combination with MDM2 Inhibition Downregulates Rad51 Recombinase in a Bimodal Manner to Inhibit Homologous Recombination and Augment Tumor Cell Kill
Xiaolei Xie et al.
MOLECULAR PHARMACOLOGY (2020)
Evaluation of ct-DNA and HSA binding propensity of antibacterial drug chloroxine: Multi-spectroscopic analysis, atomic force microscopy and docking simulation
Nahid Shahabadi et al.
SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY (2020)
Breathing New Life into the Mechanisms of Platinum Resistance in Lung Adenocarcinoma
Alvaro Gonzalez-Rajal et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)
Discovering the anticancer potential of non-oncology drugs by systematic viability profiling
Steven M. Corsello et al.
NATURE CANCER (2020)
Mechanisms underlying acquired platinum resistance in high grade serous ovarian cancer - a mini review
Mudra Binju et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2019)
Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status
Angiolo Gadducci et al.
JOURNAL OF OVARIAN RESEARCH (2019)
Global patterns and trends in ovarian cancer incidence: age, period and birth cohort analysis
Yanting Zhang et al.
BMC CANCER (2019)
Platinum Resistance in Ovarian Cancer: Role of DNA Repair
Giovanna Damia et al.
CANCERS (2019)
PAX8 activates a p53-p21-dependent pro-proliferative effect in high grade serous ovarian carcinoma
Dima Ghannam-Shahbari et al.
ONCOGENE (2018)
A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress
Peter M. Bruno et al.
NATURE MEDICINE (2017)
Comparison of different sample preparation methods for platinum determination in cultured cells by graphite furnace atomic absorption spectrometry
Man Xiao et al.
PEERJ (2017)
canSAR: an updated cancer research and drug discovery knowledgebase
Joseph E. Tym et al.
NUCLEIC ACIDS RESEARCH (2016)
Novel paclitaxel formulations solubilized by parenteral nutrition nanoemulsions for application against glioma cell lines
Mohammad Najlah et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2016)
Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer
Asa Fransson et al.
JOURNAL OF OVARIAN RESEARCH (2016)
p53 protein aggregation promotes platinum resistance in ovarian cancer
Y. Yang-Hartwich et al.
ONCOGENE (2015)
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
David D. Bowtell et al.
NATURE REVIEWS CANCER (2015)
Analysis of TP53 Mutation Status in Human Cancer Cell Lines: A Reassessment
Bernard Leroy et al.
HUMAN MUTATION (2014)
Selective κ Opioid Antagonists nor-BNI, GNTI and JDTic Have Low Affinities for Non-Opioid Receptors and Transporters
Thomas A. Munro et al.
PLOS ONE (2013)
Evaluating cell lines as tumour models by comparison of genomic profiles
Silvia Domcke et al.
NATURE COMMUNICATIONS (2013)
Copper-Dependent Cytotoxicity of 8-Hydroxyquinoline Derivatives Correlates with Their Hydrophobicity and Does Not Require Caspase Activation
Saverio Tardito et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Molecular mechanisms of cisplatin resistance
L. Galluzzi et al.
ONCOGENE (2012)
Clioquinol induces DNA double-strand breaks, activation of ATM, and subsequent activation of p53 signaling
Masato Katsuyama et al.
TOXICOLOGY (2012)
Evolution of platinum resistance in high-grade serous ovarian cancer
Susanna L. Cooke et al.
LANCET ONCOLOGY (2011)
Integrated genomic analyses of ovarian carcinoma
D. Bell et al.
NATURE (2011)
Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis
W. Glenn McCluggage
PATHOLOGY (2011)
Acquired Cisplatin Resistance in Human Lung Adenocarcinoma Cells Is Associated with Enhanced Autophagy
Jing-Hua Ren et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2010)
Histone yH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers
Christophe E. Redon et al.
CLINICAL CANCER RESEARCH (2010)
Tumor cellular proteasome inhibition and growth suppression by 8-hydroxyquinoline and clioquinol requires their capabilities to bind copper and transport copper into cells
Shumei Zhai et al.
JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY (2010)
PPARα signaling mediates the synergistic cytotoxicity of clioquinol and docosahexaenoic acid in human cancer cells
Erin R. Tuller et al.
BIOCHEMICAL PHARMACOLOGY (2009)
Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2
Sarah A. Martin et al.
EMBO MOLECULAR MEDICINE (2009)
The Translesion Polymerase Rev3L in the Tolerance of Alkylating Anticancer Drugs
Wynand Paul Roos et al.
MOLECULAR PHARMACOLOGY (2009)
Use of the Rad51 promoter for targeted anti-cancer therapy
Christopher M. Hine et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Clioquinol, a therapeutic agent for Alzheimer's disease, has proteasome-inhibitory, androgen receptor-suppressing, apoptosis-inducing, and antitumor activities in human prostate cancer cells and xenografts
Di Chen et al.
CANCER RESEARCH (2007)
Anticancer activity of the antibiotic clioquinol
WQ Ding et al.
CANCER RESEARCH (2005)
Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells
KG Daniel et al.
BREAST CANCER RESEARCH (2005)
Share Paper
